These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 32490446

  • 1. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
    Datta P, Bang S, Yue Z, Beach T, Stilgenbauer M, Wang H, Bowers DJ, Kurokawa M, Xiao H, Zheng YR.
    Dalton Trans; 2020 Jun 23; 49(24):8107-8113. PubMed ID: 32490446
    [Abstract] [Full Text] [Related]

  • 2. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
    Tan MX, Wang ZF, Qin QP, Zou BQ, Liang H.
    Dalton Trans; 2020 Feb 07; 49(5):1613-1619. PubMed ID: 31942585
    [Abstract] [Full Text] [Related]

  • 3. Near-infrared light-mediated photoactivation of a platinum antitumor prodrug and simultaneous cellular apoptosis imaging by upconversion-luminescent nanoparticles.
    Min Y, Li J, Liu F, Yeow EK, Xing B.
    Angew Chem Int Ed Engl; 2014 Jan 20; 53(4):1012-6. PubMed ID: 24311528
    [Abstract] [Full Text] [Related]

  • 4. Coordination-driven self-assembly of a Pt(iv) prodrug-conjugated supramolecular hexagon.
    Yue Z, Wang H, Li Y, Qin Y, Xu L, Bowers DJ, Gangoda M, Li X, Yang HB, Zheng YR.
    Chem Commun (Camb); 2018 Jan 18; 54(7):731-734. PubMed ID: 29303526
    [Abstract] [Full Text] [Related]

  • 5. Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin.
    Ma R, Wang Y, Yan L, Ma L, Wang Z, Chan HC, Chiu SK, Chen X, Zhu G.
    Chem Commun (Camb); 2015 May 07; 51(37):7859-62. PubMed ID: 25854514
    [Abstract] [Full Text] [Related]

  • 6. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy.
    Xiao H, Yan L, Zhang Y, Qi R, Li W, Wang R, Liu S, Huang Y, Li Y, Jing X.
    Chem Commun (Camb); 2012 Nov 11; 48(87):10730-2. PubMed ID: 23012698
    [Abstract] [Full Text] [Related]

  • 7. Hybrid inorganic (nonporous silica)/organic (alginate) core-shell platform for targeting a cisplatin-based Pt(IV) anticancer prodrug.
    Ravera M, Gabano E, Bonzani D, Zanellato I, Arrais A, Cantamessa S, Biggiogera M, Osella D.
    J Inorg Biochem; 2018 Dec 11; 189():185-191. PubMed ID: 30312905
    [Abstract] [Full Text] [Related]

  • 8. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent PtIV Anticancer Prodrug.
    Ma L, Wang N, Ma R, Li C, Xu Z, Tse MK, Zhu G.
    Angew Chem Int Ed Engl; 2018 Jul 16; 57(29):9098-9102. PubMed ID: 29806087
    [Abstract] [Full Text] [Related]

  • 9. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    Ma ZY, Wang DB, Song XQ, Wu YG, Chen Q, Zhao CL, Li JY, Cheng SH, Xu JY.
    Eur J Med Chem; 2018 Sep 05; 157():1292-1299. PubMed ID: 30195239
    [Abstract] [Full Text] [Related]

  • 10. Human Serum Albumin Conjugated Nanoparticles for pH and Redox-Responsive Delivery of a Prodrug of Cisplatin.
    Shi H, Cheng Q, Yuan S, Ding X, Liu Y.
    Chemistry; 2015 Nov 09; 21(46):16547-54. PubMed ID: 26405808
    [Abstract] [Full Text] [Related]

  • 11. Alternative mechanism of action of the DNP PtIV prodrug: intracellular cisplatin release and the mitochondria-mediated apoptotic pathway.
    Krasnovskaya O, Spector D, Erofeev A, Gorelkin P, Akasov R, Skvortsov D, Trigub A, Vlasova K, Semkina A, Zyk N, Beloglazkina E, Majouga A.
    Dalton Trans; 2021 Jun 15; 50(23):7922-7927. PubMed ID: 34037020
    [Abstract] [Full Text] [Related]

  • 12. Novel hypoxia-targeting Pt(iv) prodrugs.
    Xu Z, Zhao J, Gou S, Xu G.
    Chem Commun (Camb); 2017 Mar 28; 53(26):3749-3752. PubMed ID: 28303266
    [Abstract] [Full Text] [Related]

  • 13. Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1.
    Xu Z, Hu W, Wang Z, Gou S.
    Eur J Med Chem; 2017 Dec 01; 141():211-220. PubMed ID: 29031068
    [Abstract] [Full Text] [Related]

  • 14. Functionalized nonporous silica nanoparticles as carriers for Pt(iv) anticancer prodrugs.
    Ravera M, Gabano E, Zanellato I, Perin E, Arrais A, Osella D.
    Dalton Trans; 2016 Nov 01; 45(43):17233-17240. PubMed ID: 27722707
    [Abstract] [Full Text] [Related]

  • 15. A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: a Dual-Acting Weapon for Targeting DNA in Cancer Cells.
    Montagner D, Tolan D, Andriollo E, Gandin V, Marzano C.
    Int J Mol Sci; 2018 Nov 27; 19(12):. PubMed ID: 30486477
    [Abstract] [Full Text] [Related]

  • 16. Platinum(iv) prodrugs with long lipid chains for drug delivery and overcoming cisplatin resistance.
    Chen Q, Yang Y, Lin X, Ma W, Chen G, Li W, Wang X, Yu Z.
    Chem Commun (Camb); 2018 May 22; 54(42):5369-5372. PubMed ID: 29744485
    [Abstract] [Full Text] [Related]

  • 17. Strategy for Traceless Codrug Delivery with Platinum(IV) Prodrug Complexes Using Self-Immolative Linkers.
    Lee VEY, Lim ZC, Chew SL, Ang WH.
    Inorg Chem; 2021 Feb 01; 60(3):1823-1831. PubMed ID: 33464875
    [Abstract] [Full Text] [Related]

  • 18. An Anticancer PtIV Prodrug That Acts by Mechanisms Involving DNA Damage and Different Epigenetic Effects.
    Kostrhunova H, Petruzzella E, Gibson D, Kasparkova J, Brabec V.
    Chemistry; 2019 Apr 05; 25(20):5235-5245. PubMed ID: 30740808
    [Abstract] [Full Text] [Related]

  • 19. Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs?
    Schmidt C, Babu T, Kostrhunova H, Timm A, Basu U, Ott I, Gandin V, Brabec V, Gibson D.
    J Med Chem; 2021 Aug 12; 64(15):11364-11378. PubMed ID: 34342437
    [Abstract] [Full Text] [Related]

  • 20. Reprogramming axial ligands facilitates the self-assembly of a platinum(iv) prodrug: overcoming drug resistance and safer in vivo delivery of cisplatin.
    Fang T, Ye Z, Wu J, Wang H.
    Chem Commun (Camb); 2018 Aug 14; 54(66):9167-9170. PubMed ID: 30062328
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.